Register für prospektive Ergebnisse von idiopathischer Lungenfibrose und interstitiellen Lungenerkrankungen (IPF/ILD-PRO)
Idiopathische Lungenfibrose prospektive Ergebnisse (IPF-PRO) und chronisch fibrosierende interstitielle Lungenerkrankung mit progressivem Phänotyp prospektive Ergebnisse (IPF-PRO/ILD-PRO) Register
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Rosalia Blanco
- Telefonnummer: 919-660-0890
- E-Mail: rosalia.blanco@duke.edu
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Rekrutierung
- University of Alabama - Birmingham
-
Hauptermittler:
- Tejaswini Kulkarni, MD
-
Kontakt:
- Arnissa Hopson
- Telefonnummer: 205-934-1657
- E-Mail: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85721
- Rekrutierung
- University of Arizona
-
Hauptermittler:
- Sally A Suliman, MD
-
Kontakt:
- Daniel Castaneda-Beltran
- Telefonnummer: 602-827-2347
- E-Mail: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- University of Southern California
-
Kontakt:
- Lynn Fukusima
- E-Mail: Lynn.Fukushima@med.usc.edu
-
Hauptermittler:
- Toby Maher, MD
-
Los Angeles, California, Vereinigte Staaten, 90024
- Rekrutierung
- University of California - Los Angeles
-
Hauptermittler:
- John Belperio, MD
-
Kontakt:
- Stephanie Roblero
- Telefonnummer: 310-627-2319
- E-Mail: sroblero@mednet.ucla.edu
-
Stanford, California, Vereinigte Staaten, 94305
- Rekrutierung
- Stanford University
-
Hauptermittler:
- Rishi Raj, MD
-
Kontakt:
- Summer Zhu
- Telefonnummer: 650-724-5424
- E-Mail: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- University of Colorado
-
Hauptermittler:
- Joyce Lee, MD
-
Kontakt:
- Olivia Brohl
- Telefonnummer: 303-724-0641
- E-Mail: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Hauptermittler:
- Mridu Gulati, MD
-
Kontakt:
- Maksym Minasyan
- Telefonnummer: 203-785-4177
- E-Mail: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610-3175
- Rekrutierung
- University of Florida
-
Kontakt:
- Lisbetty Lugo
- E-Mail: lisbetty.lugo@medicine.ufl.edu
-
Hauptermittler:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, Vereinigte Staaten, 33606
- Rekrutierung
- University of South Florida
-
Hauptermittler:
- Jose D Herazo-Maya, MD
-
Kontakt:
- Natasha Brown
- E-Mail: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University
-
Kontakt:
- Tracy Halabi
- Telefonnummer: 404-712-7458
- E-Mail: tracy.halaby@emory.edu
-
Hauptermittler:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, Vereinigte Staaten, 30106
- Rekrutierung
- Piedmont Healthcare
-
Hauptermittler:
- Amy Case, MD
-
Kontakt:
- Munachi (Muna) Iwotor
- Telefonnummer: 404-291-9062
- E-Mail: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago
-
Hauptermittler:
- Mary Strek, MD
-
Kontakt:
- Vanita Patel
- E-Mail: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Kontakt:
- Phillip Cooper
- Telefonnummer: 312-503-0406
- E-Mail: p-cooper@northwestern.edu
-
Hauptermittler:
- Bradford Bemiss, MD
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Rekrutierung
- Loyola University Health System
-
Hauptermittler:
- Daniel Dilling, MD
-
Kontakt:
- Sloan White
- E-Mail: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Beendet
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky
-
Hauptermittler:
- Girish Nair, MD
-
Kontakt:
- Kai Su
- Telefonnummer: 859-257-4501
- E-Mail: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Rekrutierung
- Tulane University
-
Hauptermittler:
- Joe Lasky, MD
-
Kontakt:
- Sandy Ditta
- Telefonnummer: 504-988-4040
- E-Mail: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Aktiv, nicht rekrutierend
- University of Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Henry Ford Health
-
Kontakt:
- Deepti Naidu
- Telefonnummer: 313-916-8732
- E-Mail: dnaidu1@HFHS.ORG
-
Hauptermittler:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Rekrutierung
- University of Minnesota
-
Kontakt:
- Mandi DeGrote
- Telefonnummer: 612-626-7609
- E-Mail: carl1032@umn.edu
-
Hauptermittler:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- Rekrutierung
- University of Mississippi Medical Center
-
Hauptermittler:
- Kimberly Dobbs, MD
-
Kontakt:
- Leadeashia Brackett
- Telefonnummer: 601-496-7814
- E-Mail: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University
-
Hauptermittler:
- Tonya Russell, MD
-
Kontakt:
- Mona Noroozi
- Telefonnummer: 314-362-3705
- E-Mail: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Weill Medical College of Cornell University
-
Hauptermittler:
- Kerri Aronson, MD
-
Kontakt:
- Alicia Morris
- Telefonnummer: 646-692-2741
- E-Mail: ajm2017@med.cornell.edu
-
New York, New York, Vereinigte Staaten, 10016
- Aktiv, nicht rekrutierend
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27514
- Rekrutierung
- UNC Chapel Hill
-
Hauptermittler:
- Jason Lobo, MD
-
Kontakt:
- Jackson Pettee
- E-Mail: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Rekrutierung
- Duke University
-
Hauptermittler:
- Lake Morrison, MD
-
Kontakt:
- Lauren Gray
- Telefonnummer: 919-684-7317
- E-Mail: lauren.gray@duke.edu
-
Greensboro, North Carolina, Vereinigte Staaten, 27403
- Rekrutierung
- Pulmonix LLC
-
Hauptermittler:
- Murali Ramaswamy, MD
-
Kontakt:
- Mei Zheng
- Telefonnummer: 336-522-8870
- E-Mail: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Beendet
- PMG Research
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Wake Forest Baptist Health
-
Kontakt:
- Bob Hmieleski
- Telefonnummer: 336-713-8550
- E-Mail: bhmieles@wakehealth.edu
-
Hauptermittler:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- Aktiv, nicht rekrutierend
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic
-
Hauptermittler:
- Brian Southern, MD
-
Kontakt:
- Ron Wehrmann
- Telefonnummer: 2164450574
- E-Mail: wehrmar@ccf.org
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- The Ohio State University
-
Kontakt:
- Benjamin Hood
- E-Mail: benjamin.hood2@osumc.edu
-
Hauptermittler:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma
-
Hauptermittler:
- Jad Kebbe, MD
-
Kontakt:
- Maria Mason
- Telefonnummer: 405-271-6173
- E-Mail: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97220
- Rekrutierung
- Oregon Clinic
-
Hauptermittler:
- David Hotchkin, MD
-
Kontakt:
- Meg Day
- Telefonnummer: 503-963-3182
- E-Mail: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Rekrutierung
- Penn State College of Medicine - Hershey
-
Hauptermittler:
- Rebecca Bascom, MD
-
Kontakt:
- Tim Sheehan
- Telefonnummer: 717-531-2925
- E-Mail: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Rekrutierung
- Temple University
-
Hauptermittler:
- Rachel Criner, MD
-
Kontakt:
- Luis Cardenas-Osorio
- Telefonnummer: 215-707-3311
- E-Mail: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19144
- Rekrutierung
- Thomas Jefferson University
-
Hauptermittler:
- Ross Summer, MD
-
Kontakt:
- Ramya Talluri, BSN, RN
- E-Mail: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Hauptermittler:
- Timothy Whelan, MD
-
Kontakt:
- Audra Wiser
- E-Mail: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University
-
Kontakt:
- James Del Greco
- Telefonnummer: 615-343-7068
- E-Mail: james.del.greco@vumc.org
-
Hauptermittler:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75235
- Rekrutierung
- University of Texas Southwestern
-
Hauptermittler:
- John Fitzgerald, MD
-
Kontakt:
- Meagan Galvan
- Telefonnummer: 214-645-6489
- E-Mail: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, Vereinigte Staaten, 75246
- Rekrutierung
- Baylor University Medical Center at Dallas
-
Hauptermittler:
- Yolanda Mageto, MD
-
Kontakt:
- Mary Alayo
- Telefonnummer: 214-820-6276
- E-Mail: Mary.Alayo@BSWHealth.org
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Baylor College of Medicine
-
Hauptermittler:
- Ivan Rosas, MD
-
Kontakt:
- Maria C Perea
- E-Mail: Maria.Perea@bcm.edu
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Houston Methodist Lung Center
-
Hauptermittler:
- Zeenat Safdar, MD
-
Kontakt:
- Laura Valecillos Loukidis
- Telefonnummer: 346-238-4637
- E-Mail: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- The University of Texas Health Science Center At Houston
-
Hauptermittler:
- Rodeo Abrencillo, MD
-
Kontakt:
- Beverly Rios
- Telefonnummer: 713-486-6152
- E-Mail: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- Rekrutierung
- University of Utah
-
Kontakt:
- Adeline Langer
- Telefonnummer: 801-581-5811
- E-Mail: adeline.langer@hsc.utah.edu
-
Hauptermittler:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, Vereinigte Staaten, 84111
- Rekrutierung
- Intermountain Health
-
Kontakt:
- Aisha Skowyra
- Telefonnummer: 801-507-2439
- E-Mail: Aisha.fairclough@imail.org
-
Hauptermittler:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, Vereinigte Staaten, 05446
- Aktiv, nicht rekrutierend
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Aktiv, nicht rekrutierend
- University from Virginia
-
Falls Church, Virginia, Vereinigte Staaten, 22042-3307
- Rekrutierung
- Inova Health Care Services
-
Kontakt:
- Taruni Maganti
- Telefonnummer: 703-776-3230
- E-Mail: Taruni.Maganti@inova.org
-
Hauptermittler:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Aktiv, nicht rekrutierend
- The Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Beschreibung
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Zeitfenster: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- Pro00046131
- 1199.174 (Andere Kennung: DCRI)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .